MMP-mediated degradation products of collagens, studied extensively as diagnostic biomarkers in BC, were recently associated with patient outcomes—specifically, in two independent cohorts of metastatic BCs: hormone receptor-positive and HER2-positive. Here, ERBB2 is linked to breast cancer.